Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kurokawa, K.
Right arrow Articles by Yamanaka, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurokawa, K.
Right arrow Articles by Yamanaka, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 32:466-471 (2002)
© 2002 Foundation for Promotion of Cancer Research

Salvage External Beam Radiotherapy for Local Recurrence without Systemic Progression or Prostate Specific Antigen Recurrence of Prostate Cancer after Initial Hormonal Therapy: Is It Possible to Identify Patients Likely to Have Good Treatment Outcomes?

Kohei Kurokawa, Kazuto Ito, Kazuhiro Suzuki, Yoshihiro Ono, Takumi Yamamoto, Tetsuo Akimoto and Hidetoshi Yamanaka+,§

Department of Urology and Radiology, Gunma University School of Medicine, Maebashi, Japan

Background: We attempted to identify factors that predict the outcomes of salvage external beam radiotherapy (sEBRT) in patients who showed local recurrence without systemic progression or isolated prostate specific antigen (PSA) recurrence after initial hormonal therapy.

Methods: The subjects were 33 patients who were diagnosed as having local recurrence without systemic progression (30 cases) or isolated PSA recurrence (three cases). Of these patients, those with continuously decreasing PSA levels, which were 1.0 ng/ml or less 1–1.5 years after sEBRT, were regarded as good responders (GR) whereas the remaining patients were regarded as poor responders (nGR). Survival rates in these patients and factors that distinguish GR from nGR were evaluated retrospectively.

Results: The cancer-specific 10-year survival rate was 82.4% in the 33 patients, 100% in the 21 GR patients and 55% in the 12 nGR patients (P < 0.0001). Stepwise variable selection to discriminate between GR and nGR revealed that the time from sEBRT initiation to the nadir PSA was the most significant factor (P = 0.000097). Before sEBRT, GR can be predicted in patients with pre-sEBRT PSA <30.0 ng/ml and PSA doubling time (PSADT) >7.0 months, with a sensitivity of 95.2% (20/21), a specificity of 100% and an accuracy of 97.0%.

Conclusion: Good responses to sEBRT can be expected in patients with local recurrence without systemic progression or isolated PSA recurrence after initial hormonal therapy when the patients show both pre-sEBRT PSA <30.0 ng/ml and PSADT >7.0 months.

+ For reprints and all correspondence: Kohei Kurokawa, Department of Urology, Gunma University School of Medicine, 3–39–22, Showa-machi, Maebashi, Gunma 371-8511, Japan. E-mail: kohei@showa.gunma-u.ac.jp

§ Abbreviations: sEBRT, salvage external beam radiotherapy; PSA, prostate specific antigen; GR, good responders to sEBRT; nGR, poor responders to sEBRT; PSADT, PSA doubling time; DRE, digital rectal examination; PSAV, PSA velocity; pre-sEBRT PSA, PSA before sEBRT


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.